08/06/2026 | Press release | Distributed by Public on 08/06/2026 18:46
|
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | SEC 1473 (7-02) | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. | |||
|
1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Director Stock Option (Right to Buy) | (1) | 08/15/2035 | Common Stock | 10,671 | $6.28 | D | |
| Series B Preferred Stock | (2) | (2) | Common Stock | 578,524 | (2) | I | By Brahma BlossomHill Partners, LLC(3) |
| Reporting Owner Name / Address | Relationships | |||
| Director | 10% Owner | Officer | Other | |
|
Agrawal Sundeep C/O BLOSSOMHILL THERAPEUTICS, INC. 10255 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO, CA 92121 |
X | |||
| /s/ Vincent Liptak, Attorney-in-Fact | 08/06/2026 | |
| **Signature of Reporting Person | Date |
| * | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
| ** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
| (1) | The shares vest in 12 equal monthly installments beginning on August 15, 2025. |
| (2) | Each share of Series B Preferred Stock is convertible into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. The Series B Preferred Stock has no expiration date. |
| (3) | The securities are held of record by Brahma BlossomHill Partners, LLC ("Brahma Partners"). The Reporting Person is the founder and managing partner of Brahma Capital, LLC, which manages Brahma Partners, and may be deemed to have sole voting and/or investment power over the securities held by Brahma Partners. The Reporting Person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |